Nantahala Capital Management LLC Invests $28.82 Million in Establishment Labs Holdings Inc. $ESTA

Nantahala Capital Management LLC bought a new position in Establishment Labs Holdings Inc. (NASDAQ:ESTA) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 335,830 shares of the company’s stock, valued at approximately $28,817,572. Establishment Labs accounts for about 0.0% of Nantahala Capital Management LLC’s holdings, making the stock its 20th biggest position.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Establishment Labs by 20.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 57,215 shares of the company’s stock valued at $2,335,000 after acquiring an additional 9,557 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Establishment Labs by 1.2% during the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock worth $1,105,000 after purchasing an additional 299 shares during the period. WINTON GROUP Ltd purchased a new stake in shares of Establishment Labs during the second quarter worth about $651,000. Nebula Research & Development LLC grew its stake in shares of Establishment Labs by 27.9% in the second quarter. Nebula Research & Development LLC now owns 16,214 shares of the company’s stock worth $692,000 after purchasing an additional 3,538 shares during the last quarter. Finally, Sei Investments Co. grew its stake in shares of Establishment Labs by 13.3% in the second quarter. Sei Investments Co. now owns 48,428 shares of the company’s stock worth $2,068,000 after purchasing an additional 5,668 shares during the last quarter. 72.91% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on ESTA shares. BTIG Research boosted their price target on Establishment Labs from $96.00 to $103.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Needham & Company LLC increased their price objective on Establishment Labs from $86.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Mizuho lifted their price objective on Establishment Labs from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Citigroup upgraded Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 target price for the company in a report on Thursday, August 13th. Finally, Canaccord Genuity Group set a $105.00 price target on Establishment Labs in a research note on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Establishment Labs has a consensus rating of “Moderate Buy” and an average price target of $100.25.

Establishment Labs Price Performance

Shares of NASDAQ ESTA opened at $70.64 on Friday. Establishment Labs Holdings Inc. has a 1 year low of $36.53 and a 1 year high of $97.59. The company has a debt-to-equity ratio of 12.11, a current ratio of 3.84 and a quick ratio of 2.52. The company’s 50-day moving average is $85.00 and its 200 day moving average is $74.91. The stock has a market capitalization of $2.11 billion, a P/E ratio of -53.92 and a beta of 1.07.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.05). Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%.The company had revenue of $67.54 million during the quarter, compared to analysts’ expectations of $65.79 million. During the same quarter last year, the business earned ($0.57) earnings per share. The business’s quarterly revenue was up 31.7% on a year-over-year basis. On average, sell-side analysts expect that Establishment Labs Holdings Inc. will post -1.15 earnings per share for the current year.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.